1319734-52-5

Basic information

• Product Name: (4S,5R)-3-benzyl-5-cyclohexyl-2-oxo-oxazolidine-4-carboxylic acid
• Synonyms: (4S,5R)-3-benzyl-5-cyclohexyl-2-oxo-oxazolidine-4-carboxylic acid
• CAS NO: 1319734-52-5
• Molecular Weight: 303.358
• Mol File: 1319734-52-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (4S,5R)-3-benzyl-5-cyclohexyl-2-oxo-oxazolidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (4S,5R)-3-benzyl-5-cyclohexyl-2-oxo-oxazolidine-4-carboxylic acid(1319734-52-5)
• EPA Substance Registry System: (4S,5R)-3-benzyl-5-cyclohexyl-2-oxo-oxazolidine-4-carboxylic acid(1319734-52-5)

Safety Data

• Hazardous Substances Data: 1319734-52-5(Hazardous Substances Data)

Upstream product

• 111902-61-5 (2R,3R)-3-cyclohexyl-2,3-epoxypropan-1-ol 
• 2043-61-0 cyclohexanecarbaldehyde 
• 115362-12-4 (-)-(2S,3S)-2,3-epoxy-3-cyclohexyl-1-propanol 
• 42134-55-4 3-cyclohexyl-2-propen-1-ol 
• 4484-35-9 3-cyclohexylacrylic acid 
• 1280013-87-7 methyl (4R,5R)-3-benzyl-5-cyclohexyl-2-oxo-oxazolidine-4-carboxylate 
• 1280013-85-5 (4S,5R)-3-benzyl-5-cyclohexyl-4-(hydroxymethyl)oxazolidin-2-one 

Downstream Products

• 82655-29-6 (2S,3R)-2-(t-butoxycarbonylamino)-3-cyclohexyl-3-hydroxypropanoic acid 
• 1280013-69-5 C₂₆H₃₉N₃O₃ 
• 1280013-76-4 C₁₉H₃₃N₃O₃ 
• 674782-28-6 C₃₃H₄₃N₃O₆ 
• 461023-63-2 4-[4-(((3S)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)methyl)phenoxy]benzoic acid hydrochloride 

Relevant articles and documents

Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5- dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented.